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ABSTRACT
An HPLC method using normal phase column eluted with an aqueous solvent and detected by fluorescence was applied to analyze
sulpiride concentrations in plasma samples obtained from a comparative pharmacokinetic study. This comparative study was conducted to
determine the bioequivalence of two tablet products (Dogmatyl and Sulpin) containing sulpiride on 12 normal healthy Chinese male volunteers in a single-dose, two-period, two-sequence, two-treatment crossover design. The pharmacokinetic parameters, AUC 0-last,
AUC0-inf, and Cmax, were calculated from plasma data and compared using the SAS General Linear Model computer program. A two onesided t distribution test was also performed, as well as the 90% confidence interval method, to determine the mean difference of these three
pharmacokinetic parameters. The results suggest that these two sulpiride tablet products are bioequivalent when orally administered in a
400 mg single dose of two tablets.
Key words: sulpiride, normal phase column, bioequivalence, HPLC

INTRODUCTION
Sulpiride, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy benzamide, possesses antipsychotic, antidepressive and antiulcer effects. It has a peculiar
affinity for the D2 and D4 brain dopamine receptors with a
low frequency of extrapyramidal side effects(1). The recommended oral dose of sulpiride in the treatment of schizophrenia is 200 to 400 mg twice daily with a gradual increase based
on clinical response to a maximum of 1200 mg daily(1). Dose
reductions are recommended in patients with renal impairment(2). Sulpiride also exhibits neuroleptic and thymoleptic
properties being used in mental disorders as a behavior regulator in the psychopathology of senescence, in depression and
in schizophrenia, with a first dose of 200 mg and a daily dose
increment of 200 mg to a maximum of 800 mg. It is also used
at doses of 50 to 150 mg in the treatment of gastric or duodenal ulcers, in the treatment of the irritable colon due to psychosomatic stress, and in various vertigo syndromes.
Sulpiride is slowly and poorly absorbed from the gastrointestinal tract, with peak serum levels occurring in 2 to 6
hours; its bioavailability is approximately 27%(3). Sulpiride
does not appear to be metabolized, showing that 70 to 90% of
an intravenous dose and 15 to 25% of an oral dose is excreted unchanged in the urine. A high percentage of an oral dose
* Author for correspondence. Tel & Fax:02-23771942;
E-mail: mingsheu@tmu.edu.tw

of sulpiride has been recovered in feces; the terminal half-life
of sulpiride is 6 to 10 hours(4). The dose proportionality study
demonstrated that sulpiride followed a linear disposition
kinetic when administration of sulpiride between dose 100 to
200 mg(5).
In healthy subjects, the plasma concentration of
unchanged drug vs. time and urinary excretion rate vs. time,
following intravenous administration of sulpiride 100 mg,
were consistent with a two compartment open model. The
apparent elimination half-life was approximately 5.9 hours
and the volume of distribution at steady-state approximately
0.859 L/Kg. About 93.1 ± 6.6 % of the administered dose
was recovered unchanged in urine. Comparison of total clearance (89.8 mL/min), renal clearance (83.0 mL/min), and
renal clearance of unbound drug (97.6 mL/min) indicate that
sulpiride is mainly excreted by the renal route(5). The absorption of sulpiride was relatively slow with very large interindividual variations in the rate and the extent of absorption(6).
Due to its poor bioavailability and large individual variation, a study is needed to prove that generic products of
sulpiride are bioequivalent to the innovative product and are
clinically beneficial. The aim of the present study was to
examine comparative pharmacokinetics of two tablet formulations of sulpiride (Dogmatyl vs. Sulpin) in healthy
Chinese males with an improved and simplified HPLC
method.
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MATERIALS AND METHODS
I. Drug and Reagents
The innovative Dogmatyl 200-mg tablet (lot no. 269)
was obtained from Fujisawa Pharmaceutical Co., Taoyuan,
Taiwan. Sulpin 200-mg tablet (lot no. R870901T), made by
Sin-Tong Chemical Industrial Co. Ltd. (Taoyuan, Taiwan),
was used as the test product. The standard sulpiride and internal standard, metoclopramide, were both purchased from
Sigma Chemical (St. Louis, MO, USA). All other reagents
used were reagent or pharmaceutical grade.
II. Physical Characterizations
The potency, uniformity, and dissolution test of sulpiride in these two tablet formulations (Dogmatyl  and
Sulpin) were assayed according to the pharmacopoeia specifications (USP XXIII). Test results demonstrated that the
potency (n=20) was 99.57% and 96.27% for Dogmatyl and
Sulpin, respectively. The content uniformity of dosage
units (n=10) were 99.37±0.85% and 96.07±0.86% for
Dogmatyl and Sulpin, respectively. The results of the
potency and uniformity data of these two tablet formulations
both met the criteria of the pharmacopoeia specifications
(potency: 90-110%; uniformity: 85-115%). Three dissolution
media, including 0.1N HCl solution, pH4.5 acetate buffer,
and pH6.8 phosphate buffer solutions were employed to
compare the dissolution profiles of these two products using
Dissolution Apparatus II (stirring rate = 50 rpm; temperature
= 37˚C; n = 6). The closeness of profiles was statistically
determined by comparison of the f2 value following the
guidelines of SUPAC IR(7).
III. Assay Method
The preparation and extraction method of plasma samples have been reported(8) and are summarized as follows.
Plasma sample (1 mL) was spiked with 0.1 mL internal standard (metoclopramide, 1.5 µg/mL in methanol) solution and
0.1 mL NaOH solution (1N). After vortex mixing thoroughly
for 5 s, the mixture was extracted with 6 mL of ethylacetate/dichloromethane (5:1 v/v), then vortex mixing for 5
min, and centrifuged at 4000 rpm for 10 min. The supernatant
(organic phase) is transferred to another clean glass tube and
evaporated under a stream of nitrogen gas at 40˚C until completely dry. Next, 0.2 mL of mobile phase was added to dissolve the residue, and 0.1ÉnmL was injected automatically
into the HPLC system for analysis.
The HPLC system consists of a pump (Jasco PU-980
Intelligent HPLC Pump, Tokyo, Japan) and an autosampler
(Jasco AS-950-10 Intelligent Sampler, Tokyo, Japan). A
250×4-mm (id) normal phase column (LiChrospher Si 60,
Merck, Germany) with a particle size of 5 µm was employed.
The mobile phase consisted of triethylamine solution (0.5%,
pH 4.0), methanol and acetonitrile in the proportion of
10:5:85 (v/v). The flow rate was set at 1.8 mL/min. The elu-

ent was detected with a fluorescence detector (JASCO FP920 Fluorescence Detector, Tokyo, Japan) at the wavelength
of 300 nm for excitation and 365 nm for emission, respectively. The HPLC system was controlled by a PC workstation
installed with Borwin computer software (JMBS developments, France). The HPLC method was validated and reported in the same previous study(8). High precision and accuracy with a minimal interference and the peak of highly symmetry were demonstrated. The low limit of quantitation was
20 ng/mL with a coefficient of variation less than 20%. A linear range was found to be from 20 ng/mL to 1500 ng/mL.
This HPLC method was validated with the precision for
inter-day and intra-day run being 0.36% to 8.01% and 0.29%
to 5.25%, respectively and the accuracy (relative error of
mean, %) for inter-day and intra-day run being -1.58% to
5.02% and -2.14% to 5.21% respectively.
IV. Subjects
The protocol of the bioequivalence study was approved
by the Internal Review Board of Taipei Medical University
Hospital. A total of 12 healthy male subjects participated in
this study after signing a consent form. The subjects had a
mean ± SD age of 22 ± 2 years (20-25 years), body weight of
66 ± 6 kg (55-78 kg), and height of 172 ± 5 cm (165-184 cm).
Subjects with a history of drug allergies or idiosyncrasies,
renal or hepatic impairment, or drug or alcohol abuse were
excluded. Subjects who used medications of any kind within
2 weeks of the start or during the study were also excluded.
V. Study Design
The study was conducted in a crossover design with 12
subjects receiving a 400 mg single dose (two 200 mg tablets)
of Dogmatyl and Sulpin. Each subject was requested to
fast for at least 10 hours overnight the day before and 4 hours
after each treatment. A single dose consisting of two R
(Dogmatyl) or T (Sulpin) tablets was randomly given to
each subject with 200 mL of water. The washout period
between two periods was 1 week.
Heparinized venous blood samples (about 10 mL) were
collected by means of an indwelling venous cannula of the
cubital vein on the profiling day according to the predetermined time schedule, which included a blank sample just
prior to dosing and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12,
24, 36, 48, 52, and 60 hours after drug administration. Any
deviation from the stated sampling times was recorded.
Plasma was immediately separated by centrifugation at 3000
rpm for 10 min, then was transferred to labeled tubes, and
stored at -25 ˚C until assay.
VI. Pharmacokinetic Data Analysis
All pharmacokinetic variables were calculated by noncompartmental methods. Cmax and Tmax were obtained directly from the concentration-time curve data. The area under the
concentration-time curve from time zero (predose) to time of
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last quantifiable concentration (AUC0-last) was calculated
using the linear trapezoidal method, and Cl/F is equal to
(dose/AUC0-inf). The terminal rate constant, β, was calculated by applying a log-linear regression analysis to at least the
last three time points. T1/2 is the terminal half-life. MRT is
the mean residence time of the drug. AUMC0-last is the area
under the moment-versus-time-curve to the last sample point
and is determined using the linear trapezoidal method.
VII. Statistical Analysis
A two-way ANOVA performed with the SAS General
Linear Models Procedure at a significance level of 0.05 was
carried out. The test (T) and reference (R) treatments of each
study were compared with respect to relevant pharmacokinetic variables using an analysis of variance with subject,
treatment, and period effects with the raw data. Point estimates and 90% confidence intervals for the “T/R” mean
ratios of these raw data were calculated. Whenever there was
no statistically significant difference, statistic power to detect
at least a 20% difference between products was checked.
Bioequivalence of the test treatment to the reference treatment was assessed on the basis of the confidence intervals for
the “T/R” mean ratios of these raw variables in relation to the
bioequivalence range of 80%-120% for the raw data.

mean ratios of AUC0-last, AUC0-inf and Cmax between two
products were close to 1.0000. The results of ANOVA test of
three pharmacokinetic parameters show that the factor of the
subject was the only one determined to be significant. There
was no statistically significant group, period, or treatment
effect on these three pharmacokinetic parameters in this
crossover design.
Other pharmacokinetic parameters, such as β, Tmax,
T1/2, MRT0-inf, and CL/F, for the two products are shown in
Table 2. Insignificant difference was found for those parameters between these two products. The mean AUClast-inf was
less than 3.83% and 3.76% for Dogmatyl and Sulpin tablets.
This indicates that the estimation of AUC is more reliable
with less extent of extrapolation as a consequence of the
designed time period for sampling.
The dissolution profiles in different media of the two
tablet formulations are shown in Figure 2, which demonstrates that f2 values were 66.90, 94.27, and 85.60 for disso-

RESULTS AND DISCUSSION
Figure 1 displays the individual and the mean of sulpiride plasma concentration-time profile in 12 volunteers for the
Dogmatyl and Sulpin. The pharmacokinetic parameters
were calculated correspondingly and statistical analysis
results for two formulations of sulpiride tablets were delineated in Table 1. The ratios (mean ± SD) of AUC0-last,
AUC0-inf, and Cmax of the test drug (Sulpin) to the reference
drug (Dogmatyl) are 0.98 ± 0.11, 0.98 ± 0.10 and 1.00 ±
0.10, respectively. There was no significant difference (p >
0.05) in bioavailability between the two products as indicated by these three parameters. The 90% confidence intervals
of the mean difference were in a range of 94.16-104.31%,
93.97-103.85%, and 94.56-103.53% for AUC0-last, AUC0-inf,
and Cmax, respectively. The 90% confidence interval of the
mean difference for these three pharmacokinetic parameters
fell within the range of 80%-120%. The same results of statistical analysis were obtained using the two one-sided t distribution method. The values of statistical power to compare

Figure 1. Sulpiride plasma concentration-time profile in twelve volunteers for (A) Dogmatyl and (B) Sulpin products.

Table 1. Pharmacokinetic parameters of BE study for sulpiride tablet formulations and statistical analysis
Dogmatyl
Sulpin
Ratio (T/R)
Statistical Analysis
Parameter
Mean
Mean
Mean
F Value
90% C.I.
(SD)
(SD)
(SD)
(Pr>F)
12360.62
12266.45
0.98
0.07
94.16-104.31
AUC0-last
(ng*h/mL)
(3242.15)
(3779.49)
(0.11)
(0.7910)
12843.39
12703.24
0.98
0.16
93.97-103.85
AUC0-inf
(ng*h/mL)
(3321.76)
(3819.78)
(0.10)
(0.6975)
1030.10
1020.29
1.00
0.15
94.56-103.53
Cmax
(ng/mL)
(363.80)
(340.22)
(0.10)
(0.7084)

Power
1.0000
1.0000
1.0000
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lution in the media of 0.1 N HCl, pH 4.5 acetate buffer, and
pH 6.8 phosphate buffer solutions, respectively. An f2 value
between 50 and 100 suggests the two dissolution profiles are
similar. Since the dissolution profiles of the two products
were similar and bioequivalence was claimed for these two
products, a possible correlation between in vitro dissolution
and in vivo bioequivalence might exist.
Comparisons of pharmacokinetic parameters were made
between those obtained in this study and those reported by
Chen et. al.(9), using the same single dose of 400 mg for two
tablet formulations (Dogmatyl vs. Sulpiride) on Chinese
male volunteers. It indicates that T max (1.50 ± 0.63 vs
4.21 ± 2.27 hr) obtained in Chen’ study is much shorter than
that obtained in this study for the same formulation of
Dogmatyl, whereas Cmax (1.468 ± 0.631 vs 1.030 ± 0.364
µg/mL) is higher in Chen’s study. T1/2 (8.396 ± 1.953 vs
11.98 ± 2.12 hr) and β (0.087 ± 0.021 vs 0.0595 ±
0.0104 hr-1) for the terminal phase obtained by these two
studies are also quite different. However, AUC 0- ∝
(13.56 ± 9.09 vs 12.84 ± 3.32 µg.h/mL) of these two studies
is at a comparable level.
According to Tmax, it can be realized that the absorption
rate of sulpiride in this study was slower than that reported by
Chen et al. In turn, a lower Cmax resulted with a slower
absorption rate. However, AUC form zero to infinite was
maintained at a similar level, indicating that the bioavailability of sulpiride for these two studies could reach the same
extent after extrapolation to the infinite time. Correspondingly, the percentage of extrapolation of AUC after the last
sampling point was lower for this study (3.83 ± 1.27% vs
22.09 ± 10.78%).
On the other hand, the terminal half-life for these two
products based on the regression on the data point in the terminal phase (11.98 ± 2.12 hr for Dogmatyl and 11.49 ±
2.64 hr for Sulpin) found no significant difference statistically, (p = 0.5049), but were substantially longer than those
that have been reported as 5.3 hr (3.7-7.1 hr) for intravenous
administration of 100 mg(3), 6.39 ± 1.74 hr for oral administration of 400 mg capsule(6), 9.9 ± 1.7 hr for oral administration of 200 mg tablet(10), and 7.17 ± 1.09 hr for intramuscular
administration of 100 mg(5). A longer time period of sampling during the terminal phase might be attributed to some
extent. It was also reported by Wiesel et al. that the half-lives
for two subjects were 11.0 and 13.9 hr when the three-compartment model instead of the two-compartment model was
applied(3). Therefore, the longer half-life obtained in this
study is probably a result of being able to detect drug con-

centrations at the terminal phase in longer periods of sampling time. Alternatively, whether or not the ethnic difference
plays a role in this matter might be worthy for further study.

CONCLUSIONS
The bioequivalence study of two commercial sulpiride

Figure 2. The dissolution profiles in different medium of the two tablet
formulations. (A) 0.1 N HCl, (B) pH 4.5 acetate buffer, (C) pH 6.8
phosphate buffer.

Table 2. Pharmacokinetic parameters of sulpiride tablet formulations other than pivotal parameters
Dogmatyl
Sulpin
Parameter
Mean (SD)
CV (%)
Mean (SD)
β (hr-1)
0.0595 (0.0104)
17.42
0.0633 (0.0144)
4.21 (2.27)
53.96
3.83 (1.79)
Tmax (hr)
11.98 (2.12)
17.70
11.49 (2.64)
T1/2 (hr)
15.98 (2.72)
17.01
15.35 (2.29)
MRT0-inf (hr)
CL/F (L/hr)
33.54 (10.61)
31.63
35.31 (14.57)
AUClast-inf (%)
3.83 (1.27)
33.13
3.76 (1.99)

CV (%)
22.73
46.64
22.95
14.89
41.26
52.83
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200 mg tablets (Dogmatyl vs. Sulpin) with a 400 mg single-dosed of two tablets oral administration in 12 healthy,
normal male volunteers was conducted. The statistical analysis results based on comparisons of three pharmacokinetic
parameters (AUC0-last, AUC0-inf and Cmax) showed that these
two tablet products appear to be bioequivalent.
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摘

要

應用一種配合水性溶媒移動相之正相矽膠管柱以螢光偵測的改良式高效液相層析法於比較兩種市售
Sulpiride 錠片處方（Dogmatyl 和 Sulpin）的口服藥物動力學。利用十二位健康華人男性自願者，以單劑量，
二週期，二個次序、二種交叉試驗設計比較二個產品的相等性試驗。 Sulpiride 的血漿濃度分析也經簡化為以
液相萃取鹼化的血漿樣品，再以此經確效的高效液相層析法檢測。由血漿數據計算的主要藥動學參數包括
AUC0-last 、 AUC0-inf 、與 Cmax ，並利用 SAS 電腦軟體進行統計分析比較。 Two one-sided t distribution 和 90%
可信賴度區間用來比較三個主要參數的平均差異性。結果顯示當口服使用二種單劑量 400 毫克的二顆錠片產
品具有生體相等性。
關鍵詞：正相矽膠管柱， Sulpiride ，生體相等性，高效液相層析法

